Abstract
Androgenetic alopecia (AGA) is the most common hair loss condition affecting between 40% to 50% of Canadian men and women by 50 years of age. This nonscarring hereditary condition can significantly affect patients, impacting their overall well-being and quality of life. Despite the multitude of interventions and the willingness of people with AGA to try treatments, there are no clear Canadian guidelines on its management. An expert panel of 11 physicians developed Delphi-based consensus recommendations of interventions for the management of AGA in male and female adults. Forty-five interventions were reviewed. Seven interventions are recommended, including oral dutasteride; oral finasteride; topical finasteride; topical minoxidil; platelet-rich plasma; microneedling; and oral minoxidil. Five interventions are recommended with near consensus: intralesional dutasteride; ketoconazole shampoo; low level laser therapy; aminexil; as part of a regimen and 17 are not recommended (adenosine; cetirizine; carboxytherapy; amla syrup; microfilament thread; Nourkrin; injectable minoxidil; caffeine; ceramide; topical herbal formulations; piroctone olamine shampoo or leave-on; rosemary oil; shampoo and lotion hair care products containing fermented papaya, fermented mangosteen, and caffeine; basic Fibroblast Growth Factor (bFGF); flutamide).
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
